Home  /  Resource Library  /  Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study

Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study

Results of a study investigating acalabrutinib for treatment of follicular lymphoma.

Related Articles

Editorial Guidelines

To ensure the integrity of all content produced by the Lymphoma Coalition (LC), a rigorous process has been put

Learn More

Transparency With Corporations...

This document outlines LC’s policy on commercial funding and provides a set of principles that will be used to guide LC’s decisions. It does not...

Learn More